Literature DB >> 31611195

Altered RNA Processing in Cancer Pathogenesis and Therapy.

Esther A Obeng1, Connor Stewart2, Omar Abdel-Wahab3.   

Abstract

Major advances in our understanding of cancer pathogenesis and therapy have come from efforts to catalog genomic alterations in cancer. A growing number of large-scale genomic studies have uncovered mutations that drive cancer by perturbing cotranscriptional and post-transcriptional regulation of gene expression. These include alterations that affect each phase of RNA processing, including splicing, transport, editing, and decay of messenger RNA. The discovery of these events illuminates a number of novel therapeutic vulnerabilities generated by aberrant RNA processing in cancer, several of which have progressed to clinical development. SIGNIFICANCE: There is increased recognition that genetic alterations affecting RNA splicing and polyadenylation are common in cancer and may generate novel therapeutic opportunities. Such mutations may occur within an individual gene or in RNA processing factors themselves, thereby influencing splicing of many downstream target genes. This review discusses the biological impact of these mutations on tumorigenesis and the therapeutic approaches targeting cells bearing these mutations. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31611195      PMCID: PMC6825565          DOI: 10.1158/2159-8290.CD-19-0399

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  128 in total

1.  Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Authors:  Craig M Bielski; Mark T A Donoghue; Mayur Gadiya; Aphrothiti J Hanrahan; Helen H Won; Matthew T Chang; Philip Jonsson; Alexander V Penson; Alexander Gorelick; Christopher Harris; Alison M Schram; Aijazuddin Syed; Ahmet Zehir; Paul B Chapman; David M Hyman; David B Solit; Kevin Shannon; Sarat Chandarlapaty; Michael F Berger; Barry S Taylor
Journal:  Cancer Cell       Date:  2018-11-01       Impact factor: 31.743

2.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

3.  Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types.

Authors:  Zheng Xia; Lawrence A Donehower; Thomas A Cooper; Joel R Neilson; David A Wheeler; Eric J Wagner; Wei Li
Journal:  Nat Commun       Date:  2014-11-20       Impact factor: 14.919

4.  3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk.

Authors:  Hyun Jung Park; Ping Ji; Soyeon Kim; Zheng Xia; Benjamin Rodriguez; Lei Li; Jianzhong Su; Kaifu Chen; Chioniso P Masamha; David Baillat; Camila R Fontes-Garfias; Ann-Bin Shyu; Joel R Neilson; Eric J Wagner; Wei Li
Journal:  Nat Genet       Date:  2018-05-21       Impact factor: 38.330

5.  Interaction between the RNA binding domains of Ser-Arg splicing factor 1 and U1-70K snRNP protein determines early spliceosome assembly.

Authors:  Suhyung Cho; Amy Hoang; Rahul Sinha; Xiang-Yang Zhong; Xiang-Dong Fu; Adrian R Krainer; Gourisankar Ghosh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

6.  Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.

Authors:  Brenton R Paolella; William J Gibson; Laura M Urbanski; John A Alberta; Travis I Zack; Pratiti Bandopadhayay; Caitlin A Nichols; Pankaj K Agarwalla; Meredith S Brown; Rebecca Lamothe; Yong Yu; Peter S Choi; Esther A Obeng; Dirk Heckl; Guo Wei; Belinda Wang; Aviad Tsherniak; Francisca Vazquez; Barbara A Weir; David E Root; Glenn S Cowley; Sara J Buhrlage; Charles D Stiles; Benjamin L Ebert; William C Hahn; Robin Reed; Rameen Beroukhim
Journal:  Elife       Date:  2017-02-08       Impact factor: 8.140

7.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Authors:  Esther A Obeng; Ryan J Chappell; Michael Seiler; Michelle C Chen; Dean R Campagna; Paul J Schmidt; Rebekka K Schneider; Allegra M Lord; Lili Wang; Rutendo G Gambe; Marie E McConkey; Abdullah M Ali; Azra Raza; Lihua Yu; Silvia Buonamici; Peter G Smith; Ann Mullally; Catherine J Wu; Mark D Fleming; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

8.  Increased levels of noisy splicing in cancers, but not for oncogene-derived transcripts.

Authors:  Lu Chen; Jaime M Tovar-Corona; Araxi O Urrutia
Journal:  Hum Mol Genet       Date:  2011-08-23       Impact factor: 6.150

9.  Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia.

Authors:  Shih-Han Lee; Irtisha Singh; Sarah Tisdale; Omar Abdel-Wahab; Christina S Leslie; Christine Mayr
Journal:  Nature       Date:  2018-08-27       Impact factor: 49.962

10.  A general definition and nomenclature for alternative splicing events.

Authors:  Michael Sammeth; Sylvain Foissac; Roderic Guigó
Journal:  PLoS Comput Biol       Date:  2008-08-08       Impact factor: 4.475

View more
  39 in total

1.  Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.

Authors:  Otto Kauko; Susumu Y Imanishi; Evgeny Kulesskiy; Laxman Yetukuri; Teemu Daniel Laajala; Mukund Sharma; Karolina Pavic; Anna Aakula; Christian Rupp; Mikael Jumppanen; Pekka Haapaniemi; Luyao Ruan; Bhagwan Yadav; Veronika Suni; Taru Varila; Garry L Corthals; Jüri Reimand; Krister Wennerberg; Tero Aittokallio; Jukka Westermarck
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

Review 2.  RNA-biology ruling cancer progression? Focus on 3'UTRs and splicing.

Authors:  Ayse Elif Erson-Bensan
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 3.  Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics.

Authors:  Qiu Peng; Yujuan Zhou; Linda Oyang; Nayiyuan Wu; Yanyan Tang; Min Su; Xia Luo; Ying Wang; Xiaowu Sheng; Jian Ma; Qianjin Liao
Journal:  Mol Ther       Date:  2021-11-15       Impact factor: 11.454

Review 4.  CircHIPK3: a promising cancer-related circular RNA.

Authors:  Yalu Zhang; Qiaofei Liu; Quan Liao
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

5.  Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program.

Authors:  Kathryn T Bieging-Rolett; Alyssa M Kaiser; David W Morgens; Anthony M Boutelle; Jose A Seoane; Eric L Van Nostrand; Changyu Zhu; Shauna L Houlihan; Stephano S Mello; Brian A Yee; Jacob McClendon; Sarah E Pierce; Ian P Winters; Mengxiong Wang; Andrew J Connolly; Scott W Lowe; Christina Curtis; Gene W Yeo; Monte M Winslow; Michael C Bassik; Laura D Attardi
Journal:  Mol Cell       Date:  2020-11-05       Impact factor: 17.970

Review 6.  RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets.

Authors:  Yang Pan; Kathryn E Kadash-Edmondson; Robert Wang; John Phillips; Song Liu; Antoni Ribas; Richard Aplenc; Owen N Witte; Yi Xing
Journal:  Trends Pharmacol Sci       Date:  2021-04       Impact factor: 14.819

Review 7.  The role of mRNA in the development, diagnosis, treatment and prognosis of neural tumors.

Authors:  Yiyang Zheng; Yanyan Luo; Xixi Chen; Huiting Li; Baojun Huang; Baofeng Zhou; Liqing Zhu; Xianhui Kang; Wujun Geng
Journal:  Mol Cancer       Date:  2021-03-05       Impact factor: 27.401

Review 8.  Splicing regulation in hematopoiesis.

Authors:  Sisi Chen; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2021-07-01       Impact factor: 3.218

9.  Germline heterozygous mutations in Nxf1 perturb RNA metabolism and trigger thrombocytopenia and lymphopenia in mice.

Authors:  Stéphane Chappaz; Charity W Law; Mark R Dowling; Kirstyn T Carey; Rachael M Lane; Linh H Ngo; Vihandha O Wickramasinghe; Gordon K Smyth; Matthew E Ritchie; Benjamin T Kile
Journal:  Blood Adv       Date:  2020-04-14

10.  RNA pull-down confocal nanoscanning (RP-CONA) detects quercetin as pri-miR-7/HuR interaction inhibitor that decreases α-synuclein levels.

Authors:  Siran Zhu; Nila Roy Choudhury; Saul Rooney; Nhan T Pham; Joanna Koszela; David Kelly; Christos Spanos; Juri Rappsilber; Manfred Auer; Gracjan Michlewski
Journal:  Nucleic Acids Res       Date:  2021-06-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.